Asco 2025 · Posters · Terapias en desarrollo Volver

TERAPIAS EN DESARROLLO

  • Inmunoterapia
Oriol Mirallas, MD, MS

Ultrasensitive ctDNA profiling to identify long-term survivors in phase I immunotherapy trials.

Oriol Mirallas, MD, MS

Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)

playAcceso
  • Terapias moleculares dirigidas y tumores biológicos
Javier Torres-Jiménez, MD

First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.

Javier Torres-Jiménez, MD

Hospital Universitario 12 de Octubre, Madrid

playAcceso
Valentina Boni, MD, PhD

OMX-0407: A novel spectrum-selective small molecule kinase inhibitor in advanced/metastatic solid tumors.

Valentina Boni, MD, PhD

NEXT Madrid Universitary Hospital Quironsalud Madrid

playAcceso
María Gion, MD, PhD

Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.

María Gion, MD, PhD

IOB Madrid, Institute of Oncology, Hospital Beata María Ana

playAcceso
Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo